Research Topics
| Jakob DupontSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?J Dupont
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Int J Gynecol Cancer 16:68-73. 2006..28 months) and TD (17.75 months) (P= NS). Platinum sensitivity did not affect median OS based on sequence. Based on duration, toxicity, and OS there is no advantage of one sequence of D and T when treating patients with recurrent EOC...- Early detection and prognosis of ovarian cancer using serum YKL-40Jakob Dupont
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 22:3330-9. 2004..YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer... - Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumorsJakob Dupont
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 22:3366-74. 2004..To determine maximum tolerated dose, pharmacokinetics (PK), and safety of Ro 31-7453, a novel, oral cell-cycle inhibitor... - Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasCarol Aghajanian
Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:1082-8. 2007..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated... - Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioningMartee L Hensley
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 102:270-7. 2006.... - A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumorsMartee L Hensley
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Invest New Drugs 25:335-41. 2007..Attempts to increase the dose of BMS-247550 by decreasing the gemcitabine dose did not sufficiently ameliorate myelosuppression. Stable disease was observed in some patients with prior taxane exposure... - Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancerCatherine S M Diefenbach
Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 104:435-42. 2007..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer... - CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapyMargrit M Juretzka
Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 104:176-80. 2007..A secondary objective was to assess the relationship of CA125 level to PFS... - Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survivalCatherine S M Diefenbach
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer 107:1511-9. 2006..LPAAT-beta is an intriguing prognostic tool for the identification of high-risk EOC and a potential target for directed therapy that warrants further study... - Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective studyMika A Sovak
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 103:451-7. 2006..CONCLUSION: TC is a well tolerated, active regimen in the treatment of resected, high-risk stage III and IV endometrial cancer that warrants further investigation... - Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancerPaul Sabbatini
Memorial Sloan-Kettering Cancer Center, New York, New York, Franklin Square Hospital, Baltimore, MD, USA, and University of Marburg, Germany
Clin Cancer Res 12:5503-10. 2006..CONCLUSIONS: Immunization with abagovomab is well tolerated and induced robust Ab3 responses at the two doses and routes tested. A phase III randomized study with abagovomab (2.0 mg s.c.) is warranted... 
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomasXingxing Zang
Howard Hughes Medical Institute, Immunology Program, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Mod Pathol 23:1104-12. 2010..B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas...- Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinomaPaul Sabbatini
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 22:4523-31. 2004..To evaluate the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamic acid, in heavily pretreated patients with recurrent ovarian, fallopian tube, or peritoneal cancer... - Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II TrialPaul Sabbatini
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 10:2962-7. 2004..p. cisplatin with i.p. gemcitabine in patients with persistent disease at second-look assessment, the toxicity of this regimen, and the time to treatment failure and overall survival... - Weekly topotecan for recurrent endometrial cancer: a case series and review of the literatureTiffany A Traina
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Gynecol Oncol 95:235-41. 2004..Topotecan on a weekly bolus schedule should be evaluated in prospective trials to better establish its role in the treatment of recurrent endometrial cancer... 
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remissionCatherine S M Diefenbach
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 14:2740-8. 2008..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...- Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumorsWilliam P Tew
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 16:358-66. 2010..To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent... - Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experienceDon S Dizon
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY New York 10021, USA
Gynecol Oncol 91:584-90. 2003..In addition, we sought to compare these results to the outcomes in women who received carboplatin and paclitaxel (C + T) at first relapse... - Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcomaMario M Leitao
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Cancer 101:1455-62. 2004..ER, PR, and AR expression was observed in approximately 30-40% of uterine LMS cases. In the current series, PR and AR expression appeared to be associated with disease-free survival but were not found to correlate with overall survival... - Laparoscopic and hand-assisted laparoscopic splenectomy for recurrent and persistent ovarian cancerDennis S Chi
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
Gynecol Oncol 101:224-7. 2006..The purpose of this study was to report the outcomes of a series of patients who underwent splenectomy for persistent or recurrent ovarian cancer via laparoscopy or hand-assisted laparoscopy... - Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignanciesGregory M Springett
Memorial Sloan-Kettering Cancer Center, Developmental Chemotherapy Laboratory, Department of Medicine, New York, New York [corrected] USA
Cancer Res 65:9415-25. 2005..These findings identify LPAAT-beta as a potential prognostic and therapeutic target in ovarian and endometrial cancer... - Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cellsJakob Dupont
Department of Medicine, Memorial Sloan Kettering Cancer Center and the Joan and Sanford Weill Medical College of Cornell University and Immunology Program, Sloan Kettering Institute, New York, New York 10021, USA
Cancer Res 65:5417-27. 2005.... - Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarrayJakob Dupont
Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 94:449-55. 2004..We studied a large number of endometrial carcinomas to determine the range of tumors that express WT1; this could have prognostic and therapeutic significance... - Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphomaJason Konner
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 30:2294-302. 2012..To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma... - Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activityJason Konner
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Clin Colorectal Cancer 4:S81-5. 2004..VEGF Trap has demonstrated marked efficacy in halting angiogenesis and shrinking tumors in preclinical animal models and is currently being studied in phase I clinical trials in humans with advanced solid malignancies... - Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA alleleGenovefa A Papanicolaou
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Blood 102:2498-505. 2003..Furthermore, the CTL expansion obtained with AAPCs encoding full-length pp65 indicates that AAPCs may be used to present known as well as unknown CTL epitopes in the context of the AAPC's HLA... - Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerStephen A Cannistra
Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
J Clin Oncol 25:5180-6. 2007.... - Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responsesIngo Fricke
H Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida 33612, USA
Clin Cancer Res 13:4840-8. 2007..It has been proposed that inhibition of VEGF may result in improved immune responses. The goal of this study was to test this hypothesis... - The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effectsMarco Seandel
Clin Cancer Res 12:6203-4. 2006